BRD2 and pachyonychia congenita: PACT-15 was the first multicenter, open-label, Phase II RCT from Italy on resectable PC (n = 88 patients); it revealed that the PEXG regimen (comprising cisplatin, epirubicin, GEM, and capecitabine) extended the median OS to 38.2 months, thereby validating the usefulness of NAT for resectable PC [28].